A Shot in the Arm to Traditional Vaccine Trial Strategy

Vaccine clinical trials are a special kind of beast. And taming that beast faster is not just an operational challenge but also a patient access imperative.

Vaccine trials often recruit more healthy participants focused on preventative medicine rather than curative diseases, typically enrolling tens of thousands of participants for short periods of engagement. In contrast, therapeutic studies recruit patients who are treated and followed over an extended period of months and years. Despite the relatively short active observation period for participants, the volume of participants engaged globally generates vast amounts of data very quickly. As with many studies, this complexity adds cost.

A 2024 National Institutes of Health report estimates that while a typical Phase III drug trial might cost roughly $19 million, a Phase III vaccine trial can range from $60 to $148 million. And trials account for nearly 90% (including Phase IV trials) of overall vaccine development costs—especially for mRNA-based vaccines. At this price point, the industry needs to ask: is there a better, less expensive way to run trials—especially when the vaccines themselves generate such enormous societal savings?

US childhood immunization programs are estimated to have saved $540 billion in direct medical costs and $2.7 trillion in total societal savings since 1994. Adult vaccinations deliver similar returns, with comprehensive immunization programs—including COVID-19 boosters and seasonal flu vaccines—showing estimated returns of $2 to $4 for every $1 invested largely due to improved worker productivity and reduced healthcare utilization. Vaccines, too, have helped eradicate some childhood diseases while the cancer-causing human papillomavirus (HPV) vaccine given to teenagers to prevent cervical cancer shows an 88% drop in infections among teen girls and significant declines in precancers.

Given those economics and health outcomes, it is imperative for the industry to make vaccine development more efficient without compromising safety or data quality. Fortunately, there is a better way to run Phase III mega vaccine trials: standardization.

Before and after standardization

Paradoxically, participation in vaccine mega trials is relatively simple for volunteers. After consenting, participants visit a nearby trial site to receive the investigational vaccine and then provide their feedback in 30 or 60 days, often remotely using digital tools—lending such trials well to digital automation.

However, large pharmaceutical sponsors traditionally attack trial designs one at a time. The protocol is designed from scratch, and the operational design—especially around electronic clinical outcome assessments (eCOA)—is reinvented for every investigational vaccine.

Yet, foundationally, a large portion of vaccine trial design is identical from study to study. Symptom diaries, safety follow-up windows, adverse event reporting structures, and many of the patient-reported elements do not fundamentally change between, say, two influenza vaccine trials. Even so, sponsors have historically treated each vaccine study as a one-off exercise.

In a recent poll, multiple sponsors described their approach to vaccine study builds as fundamentally reactive. They admitted to designing endpoints and selecting eCOA instruments “study by study,” instead of from a coherent program or portfolio strategy. A Novartis respondent characterized eCOA selection as driven by protocol type, not portfolio logic. A Takeda representative observed that “it should not take many months to build out an eCOA in 2026,” highlighting how misaligned current timelines are with the pace of modern development.

Sponsors, CROs, and site networks describe the same diagnosis: teams can move faster, but the systems and processes inherited from an earlier era of trial design are holding them back.

One reason it still takes months is reliance on older-generation technology that can’t adapt configurations quickly and slows the critical path to go-live. But an equally large factor is the constant rebuilding of scientific rationale, endpoint strategy, and instrument configuration from scratch. Every time a new vaccine study launches, teams reinvent the wheel, reassembling the same operational components.

Consistent, reusable digital standardization changes the entire dynamic. A well-designed, standardized eCOA system can be stood up in two-four weeks and be removed from the critical path to first patient in. Instead of being a bottleneck, it becomes an accelerant to participant engagement and data quality.

Ironically, clinical teams have sophisticated, program-level strategies for nearly every other part of development—patient selection, biomarker development, regulatory sequencing, statistical analysis plans, and more. But eCOA often remains the outlier: repeatedly reinvented study by study, rather than defined once at the program level and then iterated.

A program-level eCOA strategy means that key decisions—instrument selection, recall windows, compliance thresholds, endpoint hierarchy, training flows, and device strategy—are made once, documented, and then applied across all studies in a vaccine program. Studies are no longer net-new builds but rather tailored configurations of a shared standard.

How technology and ai agents enable standardization

Modern artificial intelligence (AI)-enabled platforms are making standardization not only possible but practical. Two concepts are central:

1. Standardized vaccine diaries and assessments – Vaccine trials typically require a participant diary to track post-vaccination symptoms (reactogenicity and safety) and potential adverse events. The underlying logic and structure of these diaries are remarkably consistent: a set of yes/no (or presence/absence) questions, often with severity scales and onset/duration fields. By defining a standard eCOA assessment template that covers common safety and tolerability domains, sponsors avoid re-designing symptom tracking for every new trial. And they enjoy program-level consistency.
2. AI-generated reusable libraries – Instead of building each eCOA configuration from the ground up, agentic platforms generate a central library of reusable components (i.e., questionnaires, diaries, visit schedules, training flows, and translations) that can be assembled, tweaked, and deployed rapidly. Previously, building new libraries could take four weeks per trial. With a mature library and standardized templates, that setup time can shrink to two weeks or less.

 Key reusable assets include:

• Standard templates for vaccine diaries and other core assessments
• Reusable translations that can be applied across regions and languages
• Recurrent visit structures, reminder logic, and compliance workflows

Once in place, these libraries can be deployed consistently, time after time, across a sponsor’s vaccine portfolio. Over time, the system becomes more scalable and more powerful with every new trial.

Real-world standardization for global vaccine program

A top-10 global pharmaceutical company recently adopted a standardization strategy for eight Phase III global vaccine trials, enrolling more than 50,000 participants across two flu seasons. The company is standardizing its eCOA, training, and site-facing experience across all global regions and aiming to reuse packages for future studies.

The benefits are both immediate, with shorter study startup timelines and fewer decisions that must be re-iterated trial by trial, and compounding when applied to multiple vaccine trials across a portfolio. As the company applies these data collection and management standards across multiple vaccine trials, the savings multiply both in terms of efficiency and data consistency, compliance, and quality while aligning with international regulators’ registration expectations (such as CBER in the US). The same training modules, diary structures, translations, and workflows can be reused and improved incrementally instead of rebuilt—ultimately resulting in 50% reductions in overall eCOA build times.

Further, a consistent in-platform training experience deployed across trials ensures trial execution is uniform across all sites—and there are often hundreds of different sites involved in a mega vaccine trial. When system training is mandatory before users can access the system, every site coordinator and investigator sees the same high-quality instruction, translating into fewer helpdesk calls, less confusion, and smoother trial execution.

Before standardization, each vaccine protocol had different eCOA structures and data capture methodology. That made cross-study harmonization of data complex and created more manual workflow on data combinability to gain greater trend insights.

Once standardized, however, the pharma leader realized that, across six vaccine trials, roughly 80% of the data fields were identical (i.e., patient demographics, core safety and tolerability endpoints, etc.). With consistent structures, a sponsor can now review data and combine from multiple trials, quickly spotting trends, comparing outcomes, and managing the portfolio at a glance. Standardized data structures are also easier for regulators to review, aggregate, and interpret—particularly when sponsors seek to leverage historical data or conduct integrated analyses.

Standardization not only improves operational efficiency; it materially improves the quality, comparability, and regulatory readiness of the data.

Why sites win with standardization

Sites are often the ones bearing the operational brunt of vaccine mega trials. A single study might involve 3,000 sites recruiting hundreds of patients per day within a narrow three-month flu season window. At that pace and volume, site staff spend enormous time manually chasing patients, troubleshooting technology questions, and repeating the same training.

Standardization shifts this dynamic:

• One-time training, multi-trial benefit – Once sites are trained on a standardized platform and diary structure, they can carry that knowledge across multiple trials. The look, feel, and workflow is predictable—reducing burden on sites.
• A best-in-class, repeatable user experience – Sponsors can invest once in designing a truly intuitive, patient- and site-friendly interface. That experience is then reused, instead of continuously and furtively redesigned to dramatically reduce user friction.
• Fewer tasks, clearer focus – With standardized builds, the study team can predefine the eCOA configuration based on the ~80% of elements that are constant across a vaccine trial portfolio, then custom-configure only the remaining 20%.

This approach forces an interesting question: How important is each question or task? Often, by “trimming the fat” or removing less critical elements, sponsors can naturally reduce site and patient burden, accelerate completion and improve patient adherence.

Empowering automation at scale

A standardized trial architecture also unlocks automation that simply isn’t feasible when every study is a bespoke build. For example, when trials share consistent data models and identifiers, eConsent can automatically trigger patient creation and identification in downstream systems at scale.

Additionally, standardization allows for a mega trial’s robust volume and load testing. Mega vaccine trials must be engineered to support extremely high data throughput over short windows (i.e., tens of thousands of diary entries in a few days after vaccination). When the design is standardized, technology teams can devote less time to one-off configuration and more time to stress testing, volume planning, and performance optimization. Very few eCOA platforms today are truly proven at this combination of scale and speed; standardization is a prerequisite to get there reliably.

To succeed at scale, sponsors should:

1. Think and test for scale from the outset – Architect trials assuming high concurrency, rapid enrollment, and heavy early diary traffic. Validate not just function, but performance.
2. Verify that components and logistics scale globally – Device management must work at the level of thousands of devices, not dozens. And, regionalization (languages, date formats, local regulations) must be handled through configuration, not reinvention.

The goal is a consistent, predictable global experience for sites and patients. Technologies such as agentic automation, and integrated global logistics for device delivery all become much more powerful when used on top of a standardized foundation.

The path forward: Start once, reap the benefits repeatedly

Standardization is, at its core, about making excellence repeatable. For vaccine mega trials, that means:

• Defining a best-in-class user experience for patients and sites
• Codifying that experience into reusable templates, libraries, and workflows
• Applying those standards across an entire vaccine portfolio
• Continuously refining the 20% that is truly unique to each study, instead of rebuilding the 80% that is shared

By doing so, sponsors can reduce the cost and time to launch, improve site and patient experience, enhance data consistency, and strengthen regulatory submissions—and sustain these benefits over years and across studies. Most importantly, they can bring safe, effective vaccines to global populations faster and deliver the massive public health and economic benefits that only vaccines can. The industry is committed to getting that right. Standardization is how that commitment translates into faster, better outcomes for patients.

Every week saved in trial startup or execution is a week closer to patients having access to a vaccine. The future of vaccine development will still demand mega Phase III trials. But we no longer need to reinvent them every time. Standardization gives vaccine development the shot in the arm it has long needed.

About the author

Asad Khan has over 15 years of experience leading eClinical programs across eCOA/ePRO, CTMS, RBM, Data Analytics, and Agentic AI in clinical development. He has partnered with pharmaceutical and medical device companies of all sizes to deliver scalable, patient centric solutions that drive measurable impact across the trial lifecycle. Khan excels at the intersection of people, process, and technology, with expertise spanning customer success, operational oversight, and growth. As senior director, customer success at Medable, he drives customer engagement, fosters long term strategic partnerships, and advocates for digital transformation in clinical trials.

Khan holds an MSc. (Hons) in Clinical Research and aBSc. (Hons) in Pharmaceutical Science, and is a recognized thought leader in eCOA, decentralized trials, and agentic AI in clinical development.